Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report
Stem cell therapy for osteoarthritis: An insight
The stem cell therapy for osteoarthritis pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for osteoarthritis. Majority of the pipeline therapeutics are in early stages of development. There is no cure for the disease, but treatments are available to manage the symptoms. A long-lasting and less-frequent dose can impact overall osteoarthritis market.
The global osteoarthritis market is expected to grow at a CAGR of 8.55% over the period of 2014-2019. The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.
Covered in this report
The report covers the present scenario and the growth prospects of the stem cell therapy for osteoarthritis. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Technavio Announces the Publication of its Research Report - Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report
Technavio recognizes the following companies in the stem cell therapy for osteoarthritis: Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics.
The Stem cell therapy for osteoarthritis - A pipeline analysis report, 2017” provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under osteoarthritis stem cell therapy.
This report provides information on the therapeutic development based on the stem cell therapy for osteoarthritis dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the information of companies that are involved in the development of pipeline products. It also highlights the dormant products.
Degenerative joint disease and “wear and tear” arthritis are some of the synonyms used for osteoarthritis. It is the most common chronic condition of the joints, which features the breakdown and eventual loss of the cartilage of one or more joints. Osteoarthritis occurs mostly in knees; however, it can affect any joints such as hips, lower back, neck, small joints of the fingers, and the bases of the thumb and big toe. Osteoarthritis can occur in people of all ages and sex, but it is most common in people older than 65 years. The basic difference between rheumatoid arthritis and osteoarthritis is that the rheumatoid arthritis is an autoimmune disease characterized by an overactive, misdirected immune system while osteoarthritis is a disease of the cartilage of joints, and it is not a systemic disease or an autoimmune disease.
Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics.